Appendices: Donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease
نویسنده
چکیده
منابع مشابه
Submission on Behalf of the British Geriatrics Society to the National Institute for Clinical Excellence Health Technology Appraisal: Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia and is a progressive neurodegenerative illness for which at present there is no cure. The management involves both nonpharmacological and pharmacological approaches. This submission will concentrate mostly on the acetylcholinesterase inhibitors (AChEI), donepezil, rivastigmine and galantamine as well as the NMDA receptor antagonist m...
متن کاملThe Effects of Donepezil, Galantamine, Rivastigmine and Memantine on Mini-Mental State Examination and Mean Flow Velocity in Patients with Vascular Dementia: A Double-Blinded Randomized Clinical Trial
Background: Vascular dementia is one of the most common forms of dementia. At now, there is no treatment available to cure vascular dementia or to alter its clinical course. Some studies suggest that some drugs may be useful in controlling symptoms. The aim of this study was to evaluate the effects of donepezil, memantine, rivastigmine and galantamine on mean flow velocity and ...
متن کاملDonepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111)
Alzheimer’s disease is a serious progressive neurodegenerative disorder with devastating consequences for the patient. Donepezil has a significant body of clinical evidence, previously accepted by NICE and restated in the Eisai/Pfizer submission, that demonstrates the efficacy of donepezil in the symptomatic management of both mild and moderate AD. This evidence base shows that donepezil delays...
متن کاملTwo cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years, have been available for the treatment of Alzheimer's disease (AD) since 2011 in Japan, leading a new stage in the medical treatment of AD. We studied two AD patients showing sudden deterioration of behavioral and psychological symptoms of dementia (BPSD) associated with switching from...
متن کاملTherapeutic potentials of herbal drugs for Alzheimer’s disease—An overview
Alzheimer’s disease (AD) is a well known progressive neurodegenerative disorder having complex pathophysiology. Currently, drugs that are used symptomatically in the treatment of AD include acetylcholinesterase inhibitors (AChEIs) (rivastigmine, galantamine, donepezil) and N-methyl D-aspartate (NMDA) receptor antagonist (memantine). Limited bioavailability of these drugs stresses continuity of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2005